Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia. (15th June 2022)
- Record Type:
- Journal Article
- Title:
- Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia. (15th June 2022)
- Main Title:
- Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia
- Authors:
- Cutts, Julia C
O'Flaherty, Katherine
Zaloumis, Sophie G
Ashley, Elizabeth A
Chan, Jo Anne
Onyamboko, Marie A
Fanello, Caterina
Dondorp, Arjen M
Day, Nicholas P
Phyo, Aung Pyae
Dhorda, Mehul
Imwong, Mallika
Fairhurst, Rick M
Lim, Pharath
Amaratunga, Chanaki
Pukrittayakamee, Sasithon
Hien, Tran Tinh
Htut, Ye
Mayxay, Mayfong
Faiz, M Abdul
Takashima, Eizo
Tsuboi, Takafumi
Beeson, James G
Nosten, Francois
Simpson, Julie A
White, Nicholas J
Fowkes, Freya J I - Abstract:
- Abstract: Background: Understanding the effect of immunity on Plasmodium falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor emergence of artemisinin drug resistance. In low-transmission areas of Southeast Asia, where resistance has emerged, P. falciparum antibodies confound parasite clearance measures. However, variation in naturally acquired antibodies across Asian and sub-Saharan African epidemiological contexts and their impact on parasite clearance re yet to be quantified. Methods: In an artemisinin therapeutic efficacy study, antibodies to 12 pre-erythrocytic and erythrocytic P. falciparum antigens were measured in 118 children with uncomplicated P. falciparum malaria in the Democratic Republic of Congo (DRC) and compared with responses in patients from Asian sites, described elsewhere. Results: Parasite clearance half-life was shorter in DRC patients (median, 2 hours) compared with most Asian sites (median, 2–7 hours), but P. falciparum antibody levels and seroprevalences were similar. There was no evidence for an association between antibody seropositivity and parasite clearance half-life (mean difference between seronegative and seropositive, −0.14 to +0.40 hour) in DRC patients. Conclusions: In DRC, where artemisinin remains highly effective, the substantially shorter parasite clearance time compared with Asia was not explained by differences in the P. falciparum antibody responses studied. Abstract : TheAbstract: Background: Understanding the effect of immunity on Plasmodium falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor emergence of artemisinin drug resistance. In low-transmission areas of Southeast Asia, where resistance has emerged, P. falciparum antibodies confound parasite clearance measures. However, variation in naturally acquired antibodies across Asian and sub-Saharan African epidemiological contexts and their impact on parasite clearance re yet to be quantified. Methods: In an artemisinin therapeutic efficacy study, antibodies to 12 pre-erythrocytic and erythrocytic P. falciparum antigens were measured in 118 children with uncomplicated P. falciparum malaria in the Democratic Republic of Congo (DRC) and compared with responses in patients from Asian sites, described elsewhere. Results: Parasite clearance half-life was shorter in DRC patients (median, 2 hours) compared with most Asian sites (median, 2–7 hours), but P. falciparum antibody levels and seroprevalences were similar. There was no evidence for an association between antibody seropositivity and parasite clearance half-life (mean difference between seronegative and seropositive, −0.14 to +0.40 hour) in DRC patients. Conclusions: In DRC, where artemisinin remains highly effective, the substantially shorter parasite clearance time compared with Asia was not explained by differences in the P. falciparum antibody responses studied. Abstract : The substantially shorter Plasmodium falciparum parasite clearance time after artemisinin treatment observed in an African site, where artemisinin remains highly effective, compared with Asian sites, cannot be explained by differences in naturally acquired P. falciparum antibody responses. … (more)
- Is Part Of:
- Journal of infectious diseases. Volume 226:Number 2(2022)
- Journal:
- Journal of infectious diseases
- Issue:
- Volume 226:Number 2(2022)
- Issue Display:
- Volume 226, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 226
- Issue:
- 2
- Issue Sort Value:
- 2022-0226-0002-0000
- Page Start:
- 324
- Page End:
- 331
- Publication Date:
- 2022-06-15
- Subjects:
- malaria -- antibodies -- artemisinin -- resistance -- parasite
Communicable diseases -- Periodicals
Diseases -- Causes and theories of causation -- Periodicals
Medicine -- Periodicals
Communicable Diseases -- Periodicals
Electronic journals
616.9 - Journal URLs:
- http://jid.oxfordjournals.org/content/by/year ↗
http://www.journals.uchicago.edu/JID/journal/ ↗
http://www.jstor.org/journals/00221899.html ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/infdis/jiac232 ↗
- Languages:
- English
- ISSNs:
- 0022-1899
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5006.700000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23124.xml